Ono Pharmaceutical of Japan has appointed Gyo Sagara as executive vice president, new president and representative director of the firm. Mr Sagara replaces Daikichi Fukushima, only two months after his appointment. The firm says the move will allow Dr Fukushima to focus on improving its R&D pipeline in his new role as chairman, representative director and head of global research strategy planning.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze